Australian children as young as FIVE could be injected with Pfizer Covid vaccine in weeks
- Australian children as young as five will soon be able to jab Pfizer. to get
- TGA announced on Wednesday it will get ‘provisional provision’ for age group
- Currently, TGA is approved for the use of vaccines for children from 12 years of age
Australian children as young as five could be vaccinated soon after approval from officials.
The Therapeutic Goods Administration announced Wednesday that it has given “tentative determination” to children ages five and older to receive the Pfzier vaccine.
Currently, the TGA had approved children as young as 12 to receive the shot, but the recent classification now includes the age group from five to 11 years.
Australian children as young as five could be vaccinated soon after approval from officials (stock image)
Pfizer told AAP this week that the company had provided trial data to the U.S. regulator for an initial assessment (stock image)
“The granting of this provision means that Pfizer is now eligible to change the preliminary approval for the vaccine for children ages five to 11,” the TGA said in a statement.
“This preliminary determination is the first step in the process and does not imply that a change application has been filed by the sponsor or that such change will be provisionally approved by the TGA.”
Pfizer is now required to submit comprehensive clinical data.
Health Minister Greg Hunt said the review would happen “very quickly”, possibly within weeks.
The Therapeutic Goods Administration announced on Wednesday that it has given “tentative determination” to children ages five and older to receive the Pfzier vaccine (stock image)
He said it would also need the green light from the ATAGI technical advisory group.
“It will be reviewed very soon,” he told 4BC radio.
“We hope they (Pfizer) bring it up in the coming weeks. We have the supply and we have the distribution mechanisms.’
Pfizer told AAP this week that the company had provided research data to the U.S. regulator for an initial assessment.
A two-dose trial of the vaccine involving 2268 children had come back with favorable safety and antibody responses.
The pharmaceutical giant is also conducting a study with children aged six months to five years, which should show peak results by the end of this year.